GSK Receives US FDA Breakthrough Therapy Designation for B7-H3-Targeted Antibody-Drug Conjugate GSK5764227 in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
GSK receives US FDA Breakthrough Therapy Designation for B7-H3-targeted ADC GSK5764227 in relapsed or refractory ES-SCLC.
Related Clinical Trials
Highlighted Terms
FDAGSK5764227IASLCGSK5764227solid tumorsSCLCGlaxoSmithKlineNCT05276609esophageal carcinomaExtensive-Stage Small-Cell Lung CancerASCOGSKmetastatic castration-resistant prostate cancerHansoh Pharmanon–small cell lung cancerFDAUS FDAhead and neck squamous cell carcinomaGSK plcES-SCLCExtensive-Stage Small Cell Lung Cancer
Related News
GSK5764227 Receives Breakthrough Therapy Designation for Extensive-Stage Small Cell ...
GSK5764227, a B7-H3–targeted ADC, received FDA's Breakthrough Therapy Designation for ES-SCLC. ARTEMIS-001 study showed a 63.6% ORR and 81.8% DCR in SCLC patients, with manageable toxicity.
GSK Receives US FDA Breakthrough Therapy Designation for B7-H3-Targeted Antibody-Drug Conjugate GSK5764227 in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
GSK receives US FDA Breakthrough Therapy Designation for B7-H3-targeted ADC GSK5764227 in relapsed or refractory ES-SCLC.